Publications

1. The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.
Heine A, Held SA, Daecke SN, Riethausen K, Kotthoff P, Flores C, Kurts C, Brossart P
PLoS One. 2015 .
PMID: 26042424
2. A party of three: iNKT cells in GVHD prevention.
Heine A, Brossart P
Blood. 2015 May 28.
PMID: 26022054
3. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.
Parampalli Yajnanarayana S, Stübig T, Cornez I, Alchalby H, Schönberg K, Rudolph J, Triviai I, Wolschke C, Heine A, Brossart P, Kröger N, Wolf D
Br J Haematol. 2015 Jun .
PMID: 25824483
4. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
Heine A, Brossart P, Wolf D
Blood. 2013 Nov 28.
PMID: 24288410
5. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.
Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, Wolf D, Brossart P
Blood. 2013 Aug 15.
PMID: 23770777
6. Regulation of dectin-1-mediated dendritic cell activation by peroxisome proliferator-activated receptor-gamma ligand troglitazone.
Kock G, Bringmann A, Held SA, Daecke S, Heine A, Brossart P
Blood. 2011 Mar 31.
PMID: 21296999
7. Transfection of dendritic cells with in vitro-transcribed CMV RNA induces polyclonal CD8+- and CD4+-mediated CMV-specific T cell responses.
Heine A, Grünebach F, Holderried T, Appel S, Weck MM, Dörfel D, Sinzger C, Brossart P
Mol Ther. 2006 Feb .
PMID: 16219490